Compugen Reports 38% Revenue Decline in Q1 2026
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
compugen
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Clinical-stage biotechnology company Compugen Ltd. reported first-quarter 2026 financial results on May 17, 2026, disclosing a significant drop in revenue. Total revenue for the quarter was $1.9 million, a 38% decrease compared to the $3.1 million reported in the first quarter of 2025. The company's net loss widened to $8.5 million, or $0.09 per share, from a net loss of $6.2 million, or $0.07 per share, in the prior-year period.
Compugen's financials are inherently volatile as it is a pre-revenue company transitioning into a commercial entity. Revenue fluctuations are common and primarily tied to milestone payments from collaboration agreements, such as the one with Bayer for the COM701 program. The current quarter's decline reflects the timing of these recognized milestones rather than product sales.
The biotech sector faces a challenging macro backdrop with the XBI Biotech ETF down 12% year-to-date as of mid-May 2026. Elevated interest rates have increased the cost of capital, pressuring valuations for development-stage companies dependent on future cash flows. This environment places a premium on near-term clinical catalysts to validate pipelines and secure funding.
The immediate trigger for investor focus is the upcoming data readout for COM503, Compugen's leading anti-IL-18 binding protein candidate. The company is guiding for initial Phase 1/2 clinical data in the second half of 2026. Positive results could unlock substantial value, while a setback would exacerbate financial pressures given the company's cash position of $115 million as of March 31, 2026.
Compugen's Q1 2026 financial performance shows the challenges of a pipeline-heavy biotech. The following table contrasts key metrics with the same period last year.
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.9M | $3.1M | -38.7% |
| R&D Expenses | $7.1M | $6.8M | +4.4% |
| Net Loss | $8.5M | $6.2M | +37.1% |
| Cash & Equivalents | $115.0M | $140.2M | -18.0% |
Research and development expenses increased to $7.1 million, up from $6.8 million a year ago, reflecting continued investment in the COM503 and COM701 programs. The net loss per share of $0.09 missed the average analyst estimate of a $0.07 loss. The company's market capitalization stands at approximately $220 million, a fraction of larger immuno-oncology peers like Regeneron.
Compugen's earnings have limited direct impact on the broader biotech sector but serve as a microcosm of the risks facing early-stage oncology companies. A successful data readout for COM503 later this year would likely benefit other companies targeting the IL-18 pathway, potentially providing a sentiment boost to names like Nektar Therapeutics. Conversely, failure could cast a shadow over this specific mechanism of action.
The primary risk for Compugen is its cash burn rate. With a quarterly net loss of $8.5 million against a cash balance of $115 million, the company has a runway of approximately 3.5 years. This timeline is sufficient to reach key milestones, but any clinical delays would necessitate additional capital raises, potentially diluting existing shareholders. The lack of near-term revenue diversification beyond partnership milestones remains a structural weakness.
Positioning data indicates that short interest in CGEN remains elevated at 8% of the float, reflecting significant skepticism. Options markets are pricing in high volatility around the expected H2 2026 data catalyst. Flow has been predominantly institutional, with few retail investors engaging given the binary nature of the upcoming clinical readouts.
The entire investment thesis for Compugen hinges on two events in the second half of 2026. The first is the initial clinical data readout for the COM503 Phase 1/2 study, expected in Q3 2026. The second is the next milestone update from the Bayer partnership on COM701, anticipated in Q4 2026.
Investors should monitor the company's cash burn rate in subsequent quarters. A sustained increase beyond $9 million per quarter would shorten the projected runway and increase dilution risk. Key levels to watch for the stock include the 52-week low of $1.85 as a critical support zone. A break below this level could signal a loss of confidence ahead of the data catalyst.
If the COM503 data are positive, the stock could re-rate toward the $4-5 range, reflecting reduced clinical risk. If the data are negative or ambiguous, the stock would likely test cash value, which is approximately $1.20 per share. The outcome is entirely conditional on the specific efficacy and safety profile revealed.
Compugen does not yet sell any commercial products. Its revenue is generated entirely from collaboration and license agreements with larger pharmaceutical companies. The primary source is a multi-target partnership with Bayer AG, which includes upfront payments, milestone payments for achieving clinical and regulatory goals, and potential future royalties. The $1.9 million in Q1 2026 revenue likely represents the recognition of a specific milestone payment from this agreement.
COM503 and COM701 are two distinct immuno-oncology assets in Compugen's pipeline targeting different pathways. COM701 is a first-in-class anti-PVRIG antibody designed to enhance T-cell function. It is the more advanced asset and is the subject of the partnership with Bayer. COM503 is a potential best-in-class antibody targeting IL-18 binding protein, a newer mechanism aimed at activating NK cells and CD8+ T cells in the tumor microenvironment. It is wholly owned by Compugen.
Clinical failure of COM503 would be a significant negative event for Compugen, as it is the company's lead wholly-owned asset. The stock would likely decline sharply, potentially trading closer to its cash value per share. The company would then be entirely dependent on the partnered COM701 program for value creation, reducing its bargaining power in future collaborations and increasing its reliance on external partners like Bayer. Management would face pressure to cut R&D costs and might need to seek strategic alternatives.
Compugen's financials are a prelude to a binary clinical event in late 2026 that will determine its future.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.